BR0314219A - Inibidores do fator xa e outras serina proteases envolvidas na cascata da coagulação - Google Patents
Inibidores do fator xa e outras serina proteases envolvidas na cascata da coagulaçãoInfo
- Publication number
- BR0314219A BR0314219A BR0314219-1A BR0314219A BR0314219A BR 0314219 A BR0314219 A BR 0314219A BR 0314219 A BR0314219 A BR 0314219A BR 0314219 A BR0314219 A BR 0314219A
- Authority
- BR
- Brazil
- Prior art keywords
- factor
- inhibitors
- serine proteases
- compounds
- proteases involved
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
- C07C311/46—Y being a hydrogen or a carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
- C07D211/76—Oxygen atoms attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
- C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Hydrogenated Pyridines (AREA)
- Pyridine Compounds (AREA)
- Pyrane Compounds (AREA)
- Pyrrole Compounds (AREA)
Abstract
"INIBIDORES DO FATOR Xa E OUTRAS SERINA PROTEASES ENVOLVIDAS NA CASCATA DA COAGULAçãO". A presente invenção refere-se a derivados aminoácidos os quais apresentam efeitos inibidores do fator Xa da serina protease. A invenção também revela sais farmaceuticamente aceitáveis dos compostos, composições farmaceuticamente aceitáveis compreendendo os compostos ou seus sais, métodos para a preparação dos compostos, e métodos do seu uso como agentes terapêuticos para o tratamento ou prevenção de estados de doença em mamíferos caracterizados por trombose anormal.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40989102P | 2002-09-11 | 2002-09-11 | |
PCT/IB2003/003900 WO2004024679A1 (en) | 2002-09-11 | 2003-09-02 | Inhibitors of factor xa and other serine proteases involved in the coagulation cascade |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0314219A true BR0314219A (pt) | 2005-07-19 |
Family
ID=31994024
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0314219-1A BR0314219A (pt) | 2002-09-11 | 2003-09-02 | Inibidores do fator xa e outras serina proteases envolvidas na cascata da coagulação |
Country Status (14)
Country | Link |
---|---|
US (1) | US20040167131A1 (pt) |
EP (1) | EP1539686A1 (pt) |
JP (1) | JP2005538175A (pt) |
AR (1) | AR041219A1 (pt) |
AU (1) | AU2003260821A1 (pt) |
BR (1) | BR0314219A (pt) |
CA (1) | CA2497003A1 (pt) |
GT (1) | GT200300192A (pt) |
MX (1) | MXPA05002703A (pt) |
PA (1) | PA8582001A1 (pt) |
PE (1) | PE20041077A1 (pt) |
TW (1) | TW200409622A (pt) |
UY (1) | UY27966A1 (pt) |
WO (1) | WO2004024679A1 (pt) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7250415B2 (en) | 2003-06-04 | 2007-07-31 | Bristol-Myers Squibb Company | 1,1-Disubstitutedcycloalkyl-, glycinamidyl-, sulfonyl-amidino-, and tetrahydropyrimidinyl-containing diaminoalkyl, β-aminoacids, α-aminoacids and derivatives thereof as factor Xa inhibitors |
US7678913B2 (en) | 2004-12-07 | 2010-03-16 | Portola Pharmaceuticals, Inc. | Ureas as factor Xa inhibitors |
US9750757B2 (en) | 2013-10-29 | 2017-09-05 | Thomas Jefferson University | Methods of prevention or treatment for pathologic thrombosis or inflammation |
CN113233996B (zh) * | 2021-05-20 | 2022-05-20 | 河南大学 | 新型trpv1拮抗/faah抑制双靶点药物及其制备方法和应用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4559157A (en) * | 1983-04-21 | 1985-12-17 | Creative Products Resource Associates, Ltd. | Cosmetic applicator useful for skin moisturizing |
LU84979A1 (fr) * | 1983-08-30 | 1985-04-24 | Oreal | Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux |
US4820508A (en) * | 1987-06-23 | 1989-04-11 | Neutrogena Corporation | Skin protective composition |
US4992478A (en) * | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
US4938949A (en) * | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
DE4326465A1 (de) * | 1993-01-20 | 1995-02-09 | Thomae Gmbh Dr K | Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
ES2253782T3 (es) * | 1996-08-22 | 2006-06-01 | Warner-Lambert Company Llc | Antagonistas de receptor de bombesina no peptidicos. |
DE10036121A1 (de) * | 2000-07-25 | 2002-02-07 | Merck Patent Gmbh | N-Substituierte-1-amino-1,1-dialkyl-carbonsäurederivate |
DE10063008A1 (de) * | 2000-12-16 | 2002-06-20 | Merck Patent Gmbh | Carbonsäureamidderivate |
-
2003
- 2003-09-02 EP EP03795154A patent/EP1539686A1/en not_active Withdrawn
- 2003-09-02 JP JP2004535772A patent/JP2005538175A/ja active Pending
- 2003-09-02 AU AU2003260821A patent/AU2003260821A1/en not_active Abandoned
- 2003-09-02 MX MXPA05002703A patent/MXPA05002703A/es unknown
- 2003-09-02 BR BR0314219-1A patent/BR0314219A/pt not_active IP Right Cessation
- 2003-09-02 CA CA002497003A patent/CA2497003A1/en not_active Abandoned
- 2003-09-02 WO PCT/IB2003/003900 patent/WO2004024679A1/en not_active Application Discontinuation
- 2003-09-08 PE PE2003000909A patent/PE20041077A1/es not_active Application Discontinuation
- 2003-09-09 GT GT200300192A patent/GT200300192A/es unknown
- 2003-09-09 UY UY27966A patent/UY27966A1/es not_active Application Discontinuation
- 2003-09-10 AR ARP030103267A patent/AR041219A1/es unknown
- 2003-09-10 TW TW092125038A patent/TW200409622A/zh unknown
- 2003-09-11 PA PA20038582001A patent/PA8582001A1/es unknown
- 2003-09-11 US US10/662,046 patent/US20040167131A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2003260821A1 (en) | 2004-04-30 |
CA2497003A1 (en) | 2004-03-25 |
PA8582001A1 (es) | 2004-03-26 |
GT200300192A (es) | 2004-05-12 |
PE20041077A1 (es) | 2005-02-05 |
UY27966A1 (es) | 2004-04-30 |
AR041219A1 (es) | 2005-05-11 |
MXPA05002703A (es) | 2005-05-05 |
WO2004024679A1 (en) | 2004-03-25 |
TW200409622A (en) | 2004-06-16 |
US20040167131A1 (en) | 2004-08-26 |
EP1539686A1 (en) | 2005-06-15 |
JP2005538175A (ja) | 2005-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9815785A (pt) | Quinoxalinonas como inibidores de protease de serina tal como fator xa e trombina | |
BR9815786A (pt) | Quinolonas como inibidores de protease de serina | |
BR9815784A (pt) | Benzoxazinonas/benzotiazinonas como inibidores de protease de serina | |
BR0009042A (pt) | Composto, uso do mesmo, processo para prepararum composto, composição farmacêutica, e, métodospara tratar uma doença em um animal em que aatividade de cisteìna protease contribui para apatologia e/ou sintomatologia da doença, e paratratar uma doença em um animal em que a atividadede catepsina s contribui para a patologia e/ousintomatologia da doença | |
BR0214519A (pt) | Inibidores de fator xa e outras serina proteases envolvidas na cascata da coagulação | |
BR0317572A (pt) | Benzoxazinas e seus derivados como inibidores de pi3ks | |
BRPI0307267B8 (pt) | uso de compostos inibidores de beta-lactamases e composições farmacêuticas para terapia antibacteriana | |
BR0312232A (pt) | Inibidores de caspases e seus usos | |
BRPI0512335A (pt) | compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades e sua utilização | |
UY28778A1 (es) | Derivados de pirrol como inhibidores del factor xa | |
BR0316081A (pt) | Derivados de 2-piridona como inibidores de elastase de neutrófilo | |
BRPI0417458A (pt) | compostos inibidores de dpp-iv, sais faramaceuticamente aceitáveis e pró-fármacos do mesmo, seus processos de preparação, composição farmacêutica compreendendo os mesmos e uso dos referidos compostos na fabricação de medicamento | |
BRPI0517463A (pt) | inibidores da protease do vìrus da hepatite c, composições e tratamentos usando os mesmos | |
BRPI0513379A (pt) | derivados de sulfonamida | |
BR0116804A (pt) | Derivados fenìlicos | |
BRPI0512252A (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, formulação farmacêutica, uso de um composto, método de tratamento de uma doença, produto combinado, e, processo para a preparação de um composto | |
BRPI0519979A2 (pt) | composto ou estereoisÈmeros, misturas de estereoisÈmeros ou sais farmaceuticamente aceitáveis dos mesmos, composição farmacêutica, e, uso de um composto | |
BRPI0412761A (pt) | inibidores de serino proteases, particularmente a protease ns3-ns4a do vhc | |
BRPI0507041A (pt) | composto derivados de sulfonamida para o tratamento de doenças seus usos, processo para a preparação dos compostos e combinação de compostos | |
MX2008013836A (es) | Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos. | |
BRPI0519013A2 (pt) | composto ou esteroisÈmeros únicos, misturas de esteroisÈmeros, sais, tautÈmeros ou pró-drogas destes farmaceuticamente aceitáveis, composição farmacêutica, e, uso de um composto | |
BR0314314A (pt) | Derivados do éter 4-pirrolidina-fenil-benzìlico | |
BR0209518A (pt) | Novos derivados arilheteroalquilamina | |
BRPI0409884A (pt) | compostos, composições farmacêuticas, método para o tratamento ou porfilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos | |
BR0210548A (pt) | éteres aromáticos substituìdos como inibidores do transporte de glicina e composição farmacêutica aque os compreende |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application fees: application dismissed [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 4A , 5A , 6A E 7A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2069 DE 31/08/2010. |